

Table of contents (1) |

Foreword from Nicholas Hall	7	Pandemic cost is immense	21	Marketing Team	33
The non-prescription imperative	9	Pandemic strained ability to care	22	Professional Marketing Team	34
Rx-to-OTC switch	10	CHC has the means to advance OTC access	23	Supply Team	35
Why is Rx-to-OTC switch an imperative?	11	US FDA taking steps towards interoperability	24	Go-to-market Team	36
The current challenge for CHC	12	Interoperability connects and co-ordinates processes across the healthcare ecosystem	25	Switch strategy	37
Innovation expands reach	13	Future labelling strategies can enforce the DFL with features and benefits of interoperability	26	Switch strategy learnings	39
Non-prescription care avoids unnecessary costs to healthcare systems	14	Capabilities of interoperability will unlock complex switches	27	Drivers & barriers of switch	40
Reversing undertreatment essential	15	The non-prescription imperative	28	Switch – Drivers	41
Cost of ageing populations	16	Switch strategy	29	Switch – Barriers	42
Europe heavily impacted by NCDs	17	Switch strategy goals	30	Key switch markets	43
Improving public health and health equity	18	Switch strategy Leadership Team	31	USA	44
A new commercial opportunity	19	Regulatory and Medical Team	32	UK	48
COVID-19 spotlights health inequities	20			EU – EMA	52
				Germany	55
				France	59
				New Zealand	63

Table of contents (2) |

Australia	66	CBD – a high potential molecule	89	Under-the-counter sales	107
Japan	70	Key market switch mechanisms	91	Counterfeit medicines	108
Brazil	74	Switch can occur under several models	92	Cost vs benefit	109
OTC reimbursement can deter sales	78	USA switch mechanism	93	Cost vs benefit	110
Switch pipeline	79	UK switch mechanism	95	Case study: Flonase	111
Switch pipeline overview	80	EU Centralised Procedure switch mechanism	97	Consumers rapidly adopt digital tools	113
USA switch forecasts	81	New Zealand switch mechanism	99	Digital benefits the healthcare cycle	114
US switch difficult but rewarding	82	Australia switch mechanism	100	Consumers already gathering data	115
PDE5i switches for ED treatment	83	Japan switch mechanism	101	Health demands from wearables	116
PDE5i sales forecast; leading markets	84	Brazil switch mechanism	102	Digital consumer conversations	117
Access to DOC in West behind Asia	85	OTC exclusivity incentivises switch	103	Smartspeaker engagement	118
DOC sales forecast; leading markets	86	Inadequate exclusivity periods	104	Interactive audio ads in action	119
Triptan switch has potential in US	87	Switch without exclusivity	105	Tech innovation for self-care	120
Other CHC areas to watch	88	Reclassifying via scheduling	106	Switching to digital data collection	121
				Telehealth booms in pandemic	122

Table of contents (3) |

Test & trace	123	Switches are leading brands globally	137	Voltaren Arthritis Pain (GSK)	151
Increased capabilities to remotely test	124	US dominates switch success	138	Pataday (Alcon)	154
Pros and cons of digital testing	125	Top 10 US switches	139	APPENDIX	
Digital test and treat in action	126	ellaOne (HRA Pharma)	140	The public health case	155
Digital testing developments	127	Flonase (GSK)	141	QALY loss as a result of pandemic	156
Marketing learnings	128	Nexium 24HR / Control (GSK)	142	Mental health issues increasing	157
Marketing learnings overview	129	Viagra Connect (Viatris)	143	Reverse switch & restrictions	158
Insights from marketing learnings	130	Sildenafil switch first global in NZ	144	Factors influencing reverse switch	159
Marketing tactics overview	131	Poland first to switch sildenafil in Europe	145	Addiction cardio and overdose risks	160
Failed switches	132	ED switches on global scale low	146	Health risks driven by misuse	161
Switch successes	133	Alli (GSK)	147	Reverse switch case study: France	162
Key switches	134	Zocor Heart-Pro (J&J)	148	Global: restrictions not always effective	163
Leading global switches	135	Flomax (BI; now Sanofi)	149	Steps to be taken by manufacturers	164
Top 10 global switches	136	Oxytrol for Women (Merck / MSD; then Bayer)	150	Sources Appendix	165